Skip to main content
. 2024 Jul 29;75:103292. doi: 10.1016/j.redox.2024.103292

Fig. 4.

Fig. 4

DPP9 promotes chemoresistance by inhibiting ROS levels in liver cancer cells. (A–B) The ROS levels in SK-Hep-1 and HepG2 cells transfected with shControl + Vector, shControl + DPP9, shNQO1 + Vector, and shNQO1 + DPP9. (C–D) The ROS levels in SK-Hep-1 and HepG2 cells transfected with shControl, shDPP9 #2, shDPP9 #2 + NQO1WT, and shDPP9 #2 + NQO1Mut. (E–F) The ROS levels in SK-Hep-1 and HepG2 cells of the shControl, shDPP9 #2, and shDPP9 #2 + NAC (5 mM) groups. (G–H) Toxic effects of chemotherapy drugs (cisplatin, doxorubicin, and 5-FU) on liver cancer cells of the shControl, shDPP9 #2, and shDPP9 #2 + NAC (5 mM) groups. Data are shown as mean ± SD. ***P < 0.001 means significant difference vs. shControl + Vector or shControl group. ###P < 0.001 means significant difference vs. shDPP9 #2 group. N.S. means no significant difference.